{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:36:27Z","timestamp":1783488987680,"version":"3.55.0"},"reference-count":53,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science, Technological Development and Innovation Republic of Serbia","award":["451-03-66\/2024-03\/200110"],"award-info":[{"award-number":["451-03-66\/2024-03\/200110"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Gestational diabetes (GD) is a well known risk factor for future metabolic diseases. However, the long-term time-dependent risk of non-alcoholic fatty liver disease (NAFLD) remains unexplored. The aim of this meta-analysis was to quantify the long-term risk of NAFLD in women with previous GD and evaluate if the risk persists beyond the postpartum period. Methods: A systematic search was performed in PubMed using appropriate medical subject headings to identify trials evaluating the incidence of NAFLD among women with previous GD compared to those with normal glucose tolerance (NGT). Studies reporting adjusted risk estimates with a follow-up duration beyond pregnancy were included. Data were extracted and analyzed using relevant statistical methods, with the level of significance at p &lt; 0.05. Results: A total of four studies (N = 2873) were included in the meta-analysis. Women with previous GD had a 2.46-fold higher odds of NAFLD compared to those with NGT (95% CI 1.88\u20133.23, p &lt; 0.001). The slope for years since delivery was not significant (\u03b2 = 0.001 per year, 95% CI \u22120.037 to 0.040, p = 0.901), indicating that the likelihood of NAFLD in women with prior GD did not change over time. Conclusions: GD is associated with a substantially increased and sustained risk of NAFLD, persisting decades beyond pregnancy. These findings identified GD as a potential early risk marker of future liver outcomes and highlight the need for long-term metabolic screening and preventive strategies for this high-risk population.<\/jats:p>","DOI":"10.3390\/jcm15031209","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T09:02:01Z","timestamp":1770195721000},"page":"1209","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gestational Diabetes Associated with Postpartum NAFLD Risk Meta-Analysis: Evidence for Sustained Metabolic Dysfunction Beyond Pregnancy"],"prefix":"10.3390","volume":"15","author":[{"given":"Milica","family":"Stoiljkovic","sequence":"first","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-1899","authenticated-orcid":false,"given":"Katarina","family":"Lalic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7300-916X","authenticated-orcid":false,"given":"Tanja","family":"Milicic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-4434","authenticated-orcid":false,"given":"Ljiljana","family":"Lukic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9656-2523","authenticated-orcid":false,"given":"Marija","family":"Macesic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2969-1852","authenticated-orcid":false,"given":"Jelena Stanarcic","family":"Gajovic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-8139","authenticated-orcid":false,"given":"Mina","family":"Milovancevic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cvijanovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djurdja","family":"Rafailovic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Maric","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Vujasevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3908-5462","authenticated-orcid":false,"given":"Nina","family":"Krako Jakovljevic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-9631","authenticated-orcid":false,"given":"Kasja","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7926-3916","authenticated-orcid":false,"given":"Miroslava","family":"Gojnic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"},{"name":"Clinic for Gynecology and Obstetrics, University Clinical Centre of Serbia, Visegradska 26, 11000 Beograd, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebojsa","family":"Lalic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"},{"name":"Department of Medical Sciences, Serbian Academy of Sciences and Arts, Kneza Mihaila 35, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Jotic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Doktora Subotica 13, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Doktora Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia, 67, 2375\u20132392.","DOI":"10.1007\/s00125-024-06196-3"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type\u20092 diabetes: An update","volume":"13","author":"Lee","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_6","unstructured":"(2025). Section 15: Management of Diabetes in Pregnancy. Clin. Diabetes, 43, 223\u2013224."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12933-024-02416-7","article-title":"Gestational diabetes and long-term cardiovascular disease in mothers and offspring: Systematic review and meta-analysis","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dsi23-0013","article-title":"Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People with Type 2 Diabetes: From Bench to Patient Care","volume":"37","author":"Nogueira","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12944-017-0572-9","article-title":"A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease","volume":"16","author":"Chen","year":"2017","journal-title":"Lipids Health Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ziolkowska, S., Binienda, A., Jab\u0142kowski, M., Szemraj, J., and Czarny, P. (2021). The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011128"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., and Tiribelli, C. (2006). The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 6.","DOI":"10.1186\/1471-230X-6-33"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_15","first-page":"73","article-title":"Quantification of liver fat with magnetic resonance imaging and spectroscopy","volume":"31","author":"Reeder","year":"2010","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","article-title":"The utility of radiological imaging in nonalcoholic fatty liver disease","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vandenbroucke, J.P., von Elm, E., Altman, D.G., G\u00f8tzsche, P.C., Mulrow, C.D., Pocock, S.J., Poole, C., Schlesselman, J.J., Egger, M. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040297"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ajg.2016.57","article-title":"Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease","volume":"111","author":"Ajmera","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/1753-0407.12934","article-title":"Prospective study of gestational diabetes and fatty liver scores 9 to 16\u2009years after pregnancy","volume":"11","author":"Donnelly","year":"2019","journal-title":"J. Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00125-010-2009-0","article-title":"Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes","volume":"54","author":"Forbes","year":"2011","journal-title":"Diabetologia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/jdi.13411","article-title":"Prevalence of non-alcoholic fatty liver disease and factors associated with it in Indian women with a history of gestational diabetes mellitus","volume":"12","author":"Kubihal","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.14309\/ajg.0000000000002250","article-title":"History of Gestational Diabetes and Incident Nonalcoholic Fatty Liver Disease: The Kangbuk Samsung Health Study","volume":"118","author":"Cho","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107401","DOI":"10.1016\/j.jdiacomp.2019.06.006","article-title":"Increased risk of non-alcoholic fatty liver disease in women with gestational diabetes mellitus: A population-based cohort study, systematic review and meta-analysis","volume":"33","author":"Lavrentaki","year":"2019","journal-title":"J. Diabetes Complicat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102609","DOI":"10.1016\/j.eclinm.2024.102609","article-title":"Gestational diabetes mellitus and development of intergenerational non-alcoholic fatty liver disease (NAFLD) after delivery: A systematic review and meta-analysis","volume":"72","author":"Foo","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e001060","DOI":"10.1136\/bmjdrc-2019-001060","article-title":"\u03b2-Cell function or insulin resistance was associated with the risk of type 2 diabetes among women with or without obesity and a history of gestational diabetes","volume":"8","author":"Fan","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101294","DOI":"10.1016\/j.eclinm.2022.101294","article-title":"The life course perspective of gestational diabetes: An opportunity for the prevention of diabetes and heart disease in women","volume":"45","author":"Fu","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2147\/IJGM.S408856","article-title":"Low-Grade Inflammation in Gestational Diabetes Mellitus and Its Correlation with Maternal Insulin Resistance and Fetal Growth Indices","volume":"16","author":"Nguyen","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Varthaliti, A., Lygizos, V., Fanaki, M., Pergialiotis, V., Papapanagiotou, A., Pappa, K., Theodora, M., Daskalaki, M.A., Antsaklis, P., and Daskalakis, G. (2025). The Role of IL-6 and TNF-\u03b1 as Early Biomarkers in the Prediction and Diagnosis of Gestational Diabetes Mellitus. Biomedicines, 13.","DOI":"10.3390\/biomedicines13071627"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: Common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2119\/2007-00119.Tilg","article-title":"Inflammatory mechanisms in the regulation of insulin resistance","volume":"14","author":"Tilg","year":"2008","journal-title":"Mol. Med."},{"key":"ref_34","first-page":"1321","article-title":"NAFLD: Pathophysiology and role of inflammatory signaling","volume":"9","author":"Grander","year":"2021","journal-title":"Biomedicines"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/eje.0.1430293","article-title":"Human leptin: From an adipocyte hormone to an endocrine mediator","volume":"143","author":"Wauters","year":"2000","journal-title":"Eur. J. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Song, Q., and Zhang, X. (2022). The Role of Gut\u2013Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030524"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Liu, J., Wu, A., Cai, J., She, Z.-G., and Li, H. (2022). The contribution of the gut-liver axis to the immune signaling pathway of NAFLD. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.968799"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17562848211031394","DOI":"10.1177\/17562848211031394","article-title":"Mitochondrial dysfunction and liver disease: Role, relevance, and potential for therapeutic modulation","volume":"14","author":"Middleton","year":"2021","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_41","first-page":"47","article-title":"Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective","volume":"13","author":"Wang","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.2337\/db18-0254","article-title":"Reduced GLP-1 Secretion at 30 Minutes After a 75-g Oral Glucose Load Is Observed in Gestational Diabetes Mellitus: A Prospective Cohort Study","volume":"67","author":"Sukumar","year":"2018","journal-title":"Diabetes"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_44","first-page":"854","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis","volume":"54","author":"Gupta","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_45","first-page":"1581","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis and improves insulin signaling in hepatocytes","volume":"152","author":"Zvibel","year":"2011","journal-title":"Endocrinology"},{"key":"ref_46","first-page":"154031","article-title":"GLP-1 receptor agonist therapy ameliorates nonalcoholic steatohepatitis through suppression of hepatic inflammation and oxidative stress","volume":"103","author":"Lee","year":"2020","journal-title":"Metabolism"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.regpep.2013.08.002","article-title":"Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus","volume":"186","author":"Kosinski","year":"2013","journal-title":"Regul. Pept."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/dc15-2672","article-title":"Heterogeneous contribution of insulin sensitivity and secretion defects to gestational diabetes mellitus","volume":"39","author":"Powe","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101087","DOI":"10.1016\/j.eclinm.2021.101087","article-title":"Subtypes of gestational diabetes and future risk of pre-diabetes or diabetes","volume":"40","author":"Retnakaran","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-019-4961-7","article-title":"Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance","volume":"62","author":"Benhalima","year":"2019","journal-title":"Diabetologia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"152403","DOI":"10.1016\/j.bbrc.2025.152403","article-title":"A multi-biomarker panel for non-invasive diagnosis, risk stratification, subtype identification, and therapeutic targeting in NAFLD: Bioinformatics and experimental insights","volume":"779","author":"Zhang","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Vedtofte, L., Bahne, E., Foghsgaard, S., Bagger, J.I., Andreasen, C., Strandberg, C., G\u00f8rtz, P.M., Holst, J.J., Gr\u00f8nb\u00e6k, H., and Svare, J.A. (2020). One Year\u2019s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103213"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1209\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:10:32Z","timestamp":1770613832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15031209"],"URL":"https:\/\/doi.org\/10.3390\/jcm15031209","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]}}}